No PFS Benefit With Carotuximab in Advanced Angiosarcoma
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Researchers compared carotuximab plus pazopanib with pazopanib alone in patients with advanced angiosarcoma.
Patient age and tumor site were linked to the risk of local recurrence, and histological response to neoadjuvant chemotherapy was tied to the risk of new metastatic disease.
In a pooled analysis of 6 studies, 44% of patients responded to combination irinotecan and temozolomide.
Children prescribed a medication containing a phthalate had a 19% higher risk of developing any childhood cancer.
Black individuals had the highest incidence of osteosarcoma, but the worst survival was seen in American Indian/Alaska Native individuals.
Researchers compared patients with giant cell tumor of the bone who were treated with surgery alone or surgery plus preoperative denosumab.
Researchers sought to measure the risk of long-term neurocognitive outcomes in survivors of osteosarcoma and Ewing sarcoma.
Researchers describe the development and validation of a risk-stratification system that uses clinicopathologic factors not included in a traditional TNM staging system.
There were no significant differences between the treatment groups in rates of surgical site infections, unplanned operations, oncologic events, or all-cause mortality.
Less than 10% of radiotherapy recommendations in 2020 NCCN guidelines were category 1 recommendations.